This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00038/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00038/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n24http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB00038/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00038/identifier/national-drug-code-directory/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
n11http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://www.drugs.com/cdi/
n17http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB00038/identifier/uniprotkb/
n8http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00038/identifier/genbank/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00038
rdf:type
n3:Drug
n3:description
Oprelvekin, the active ingredient in Neumega® is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo. The primary hematopoietic activity of Neumega® is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies Neumega® has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega® improved platelet nadirs and accelerated platelet recoveries compared to controls. In animal studies Oprelvekin also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines.
n3:dosage
n14:271B4125-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
6.9 +/- 1.7 hrs
n3:indication
Increases reduced platelet levels due to chemotherapy
owl:sameAs
n19:DB00038 n24:DB00038
dcterms:title
Oprelvekin
adms:identifier
n6:P20809 n15:PA164747991 n16:Oprelvekin n21:M57765 n23:58394-004-01 n25:DB00038
n3:mechanismOfAction
Oprelvekin binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.
n3:packager
n22:271B4122-363D-11E5-9242-09173F13E4C5 n22:271B4123-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The kidney is the primary route of elimination. The amount of intact Neumega in urine was low, indicating that the molecule was metabolized before excretion.
n3:synonym
AGIF Interleukin-11 precursor IL-11 Adipogenesis inhibitory factor
n11:hasConcept
n12:M0274767
foaf:page
n10:oprelvekin.html n13:oprelvek.htm
n3:Molecular-Formula
n17:271B4129-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n17:271B4128-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:L03AC02
n3:absorption
Absolute bioavailability is over 80%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
145941-26-0
n3:category
n3:containedIn
n4:271B4124-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n17:271B4126-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n17:271B4127-363D-11E5-9242-09173F13E4C5